Walleye Capital LLC Grows Stock Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA)

Walleye Capital LLC raised its position in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 52.9% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 73,568 shares of the biotechnology company's stock after acquiring an additional 25,442 shares during the quarter. Walleye Capital LLC's holdings in ADMA Biologics were worth $1,471,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of ADMA. Public Sector Pension Investment Board bought a new stake in shares of ADMA Biologics during the 3rd quarter valued at $9,885,000. FORA Capital LLC purchased a new position in ADMA Biologics during the third quarter valued at $831,000. Healthcare of Ontario Pension Plan Trust Fund grew its holdings in ADMA Biologics by 13.9% during the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 658,900 shares of the biotechnology company's stock valued at $13,171,000 after purchasing an additional 80,400 shares during the period. BNP Paribas Financial Markets increased its position in ADMA Biologics by 12.8% in the third quarter. BNP Paribas Financial Markets now owns 750,788 shares of the biotechnology company's stock worth $15,008,000 after buying an additional 85,250 shares in the last quarter. Finally, FMR LLC raised its stake in shares of ADMA Biologics by 3.7% in the third quarter. FMR LLC now owns 1,944,831 shares of the biotechnology company's stock worth $38,877,000 after buying an additional 68,881 shares during the period. 75.68% of the stock is owned by hedge funds and other institutional investors.

ADMA Biologics Trading Down 3.7 %

ADMA Biologics stock traded down $0.74 during midday trading on Thursday, reaching $19.21. The stock had a trading volume of 938,572 shares, compared to its average volume of 3,609,564. ADMA Biologics, Inc. has a 52-week low of $3.60 and a 52-week high of $23.64. The company has a fifty day moving average of $19.09 and a 200 day moving average of $15.58. The firm has a market cap of $4.54 billion, a price-to-earnings ratio of 71.25 and a beta of 0.70. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.13 by $0.02. The company had revenue of $119.84 million for the quarter, compared to the consensus estimate of $107.25 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. During the same quarter last year, the firm posted $0.01 EPS. On average, analysts anticipate that ADMA Biologics, Inc. will post 0.52 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently issued reports on ADMA. HC Wainwright increased their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a "buy" rating in a report on Friday, November 8th. Raymond James boosted their target price on ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a research report on Friday, November 8th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $20.00 price objective on shares of ADMA Biologics in a research report on Friday, September 20th.

Insider Activity

In related news, Director Lawrence P. Guiheen sold 9,000 shares of the company's stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $18.47, for a total value of $166,230.00. Following the completion of the sale, the director now directly owns 153,941 shares of the company's stock, valued at $2,843,290.27. This represents a 5.52 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Brad L. Tade sold 15,000 shares of the stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $21.15, for a total transaction of $317,250.00. Following the transaction, the chief financial officer now owns 199,433 shares in the company, valued at approximately $4,218,007.95. The trade was a 7.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 3.70% of the company's stock.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.